Primary care and chronic disease management represent the largest patient populations in pharmaceutical medicine. The GLP-1 revolution is blurring the traditional boundary between specialty and primary care medicine. Mounjaro and Zepbound are being prescribed by endocrinologists, cardiologists, and increasingly primary care physicians — creating a commercial execution challenge for Eli Lilly that requires reaching a prescriber base of several hundred thousand physicians. The cardiovascular and metabolic disease landscape is being reshaped simultaneously by the commercial success of GLP-1 agonists and the continued growth of SGLT2 inhibitors.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Primary Care Commercial Model
• Cardiometabolic Disease
• Respiratory Disease
• Cardiovascular Disease
• IRA and Primary Care Drug Pricing
Table of Contents
1. Executive Summary
2. Market Overview
3. Primary Care Commercial Model
4. Cardiometabolic Disease
5. Respiratory Disease
6. Cardiovascular Disease
7. IRA and Primary Care Drug Pricing
8. Competitive Landscape
9. Regional Market Analysis
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Market Overview 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Portfolio and Strategy Assessment 2025
Table 3. M&A and Partnership Activity 2023-2025
Table 4. Regional Analysis
Table 5. Key Risks and Mitigation Strategies
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
